SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings...

Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?

The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2% - Time to Sell?

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 7.2% - What's Next...

<ul class="summary-bullets"><li>KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.</li><li>Through the full year 2025, the company recorded global Ekterly revenue of $49 million.</li><li>Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026.</li></ul>Shares of KalVista Pharmaceuticals, Inc. (KALV) jumped 14% after hours on Thursday after the company said that it recorded about $35 million in revenue from its one and only approved drug Ekterly in the fourth quarter, merely months after launch.KalVista <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">launched</a> Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older. The company said that in the three months through the end of December, prescription refills surpassed initial prescriptions as the primary driver of revenue.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.<h2 class="st-heading-2">Ekterly’s Edge</h2>Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Through the full year 2025, the company recorded global Ekterly revenue of $49 million. The drug is now approved in seven global markets including the U.S., United Kingdom, European Union, Switzerland, Australia, Singapore and Japan.“Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to EKTERLY,” CEO Ben Palleiko said. “Internationally, we are seeing strong uptake in Germany, with early prescribing behaviors mirroring the positive trends we observed in the US, and we expect to expand into other major markets during 2026.”Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026. The company envisions launching the drug for the younger population in the U.S. in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KalVista jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the numbers as an “incredible start to Ekterly sales.” “This has a squeeze written all over it,” the user added.<stembedurl>https://www.stocktwits.com/pblegend66/message/641279255</stembedurl>Another user highlighted the drug’s potential and noted that the company could make as much as $340 million in revenue from the drug.<stembedurl>https://www.stocktwits.com/Biocontrol/message/641276040</stembedurl><a href="https://stocktwits.com/symbol/KALV">KALV stock</a> has gained 92% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-incurs-7.1-billion-in-charges-in-q4/cmUbl4LR451">General Motors Incurs $7.1B In Charges In Q4 Pertaining To Slowing EV Demand, China Business Restructuring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.

Equity

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.


KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational...

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume - Still a Buy?

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Strong Trading Volume - What's Next...

KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00

Needham & Company LLC increased their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday...

KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% Higher - Should You Buy?

KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.1% - Here's Why...

KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the company, MarketBeat reports...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALV News

KALVKalVista Pharmaceuticals Inc